Negrier S, Mercatello A, Philip T
Département de médecine carcinologique, centre Léon-Bérard, Lyon.
Rev Prat. 1992 May 15;42(10):1241-5.
Interleukin 2 is active in metastatic renal adenocarcinoma which is usually considered as a chemoresistant tumour; 20 to 30% objective responses, including 5 to 10% complete remissions, are reported using various treatment schedules. Toxicity, though of great concern, is now controlled and IL2 is mostly used in standard oncology units or as an out-patient subcutaneous treatment. Even if IL2 is now a registered drug in France, many questions remain however, regarding the optimal schedule and dose, the interest of combining IL2 with interferon alpha or the predictive factors of response of this therapy.
白细胞介素2在转移性肾腺癌中具有活性，而转移性肾腺癌通常被认为是一种化疗耐药肿瘤；据报道，采用各种治疗方案时，客观缓解率为20%至30%，其中完全缓解率为5%至10%。毒性虽然备受关注，但现在已得到控制，白细胞介素2主要在标准肿瘤治疗单位使用，或作为门诊皮下治疗药物。即使白细胞介素2现在在法国是一种注册药物，但关于最佳治疗方案和剂量、将白细胞介素2与α干扰素联合使用的益处或该疗法反应的预测因素等问题仍然存在。
